Sanofi's Taxotere among latest Welsh recomendations
This article was originally published in Scrip
Executive Summary
In its latest final appraisals, the All Wales Medicines Strategy Group (AWMSG) has recommended Sanofi-Aventis's Taxotere (docetaxel),Novartis's Exjade (deferasirox) andSchering-Plough's Suboxone (buprenorphine with naloxone) for use in the Welsh national health service.
You may also be interested in...
Cerimon receives positive Phase II data on diclofenac patch
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Lilly's Alimta among SMC's September recommendations
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.